x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Resources for patients and caregivers.

Share these helpful tools and resources with patients with multiple myeloma and their caregivers.

POMALYST® (pomalidomide) Treatment Overview Icon

Treatment Overview

A brochure for patients who have been prescribed POMALYST® (pomalidomide).

POMALYST® (pomalidomide) Medication Guide Icon

Medication Guide

Read the Medication Guide.

POMALYST® (pomalidomide) Caregiver Brochure Icon

Caregiver Brochure

A brochure offering caregivers information and resources to help them care for patients with multiple myeloma.

POMALYST® (pomalidomide) Patient Resources Icon

Patient Resources and Tools

Explore information for patients and nurses.

See Downloads
POMALYST® (pomalidomide) Full Prescribing Information Icon

Full Prescribing Information

Explore the full Prescribing Information, including Boxed WARNINGS, for POMALYST.


POMALYST support resources
designed for HCPs.

Support Resources for HCPs

Patient Access, Reimbursement,
and Co-Pay Support.

Access and Financial Resources